SCHEMBL5734261

SCHEMBL5734261

O=C1NN(c2ccc(I)cc2)C(=O)C1=Cc1ccco1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.64
SRC P12931 4/20 0.64
NR4A1 P22736 1/20 0.64
MEN1 O00255 11/20 0.57
KMT2A Q03164 11/20 0.57
POLB P06746 8/20 0.57
ALDH1A1 P00352 5/20 0.57
MAPT P10636 5/20 0.57
L3MBTL1 Q9Y468 3/20 0.57
KDM4E B2RXH2 1/20 0.57
RECQL P46063 2/20 0.54
ITGA4 P13612 1/20 0.51
ITGB7 P26010 1/20 0.51
BLM P54132 4/20 0.48
GAA P10253 3/20 0.48
USP2 O75604 2/20 0.48
DNMT1 P26358 2/20 0.48
PPP1CA P62136 1/20 0.48
CACNA1B Q00975 1/20 0.48
APBA1 Q02410 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5734258 1.00 ABL1 (0.64) ABL1SRCNR4A1MEN1KMT2A
SCHEMBL3755954 0.88 ITGA4 (0.65) ABL1SRCNR4A1MEN1KMT2A
SCHEMBL3755958 0.88 ITGA4 (0.65) ABL1SRCNR4A1MEN1KMT2A
SCHEMBL3757779 0.87 NR4A1 (0.64) ABL1SRCNR4A1MEN1KMT2A
SCHEMBL3757780 0.87 NR4A1 (0.64) ABL1SRCNR4A1MEN1KMT2A
SCHEMBL5735689 0.86 NR4A1 (0.63) ABL1SRCNR4A1MEN1KMT2A
SCHEMBL5735693 0.86 NR4A1 (0.63) ABL1SRCNR4A1MEN1KMT2A
SCHEMBL5736034 0.85 MEN1 (0.79) ABL1SRCMEN1KMT2APOLB
SCHEMBL5736031 0.85 MEN1 (0.79) ABL1SRCMEN1KMT2APOLB
SCHEMBL5737027 0.79 ABL1 (1.00) ABL1SRCMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399156-B1 ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY APPLIED RESEARCH SYSTEMS (AN) 2006-11-22 EP disclosed
US-20040220188-A1 Alkylidene pyrazolidinedione derivatives LABORATOIRES SERONO SA (CH) 2004-11-04 US disclosed
EP-1399156-A2 ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY Applied Research Systems ARS Holding N.V. (AN) 2004-03-24 EP disclosed
WO-2002102359-A2 ALKYLIDENE PYRAZOLIDINEDIONE DERIVATIVES AND USE FOR TREATING DIABETES AND OBESITY APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2002-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220188-A1 Alkylidene pyrazolidinedione derivatives G6PC1, PPM1D, PTPRS ABL1 528/4885SRC 227/4885NR4A1 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.